The authorization comes a day after Pfizer released data suggesting that COVID-19 booster shots could be key to protection against infection from the new Omicron variant.

Pfizer previously told The Associated Press that early data from the company's booster study suggests people's antibody levels jump five-to-10-fold after a third dose.